Nottingham-based pre-clinical contract research organisation (CRO) Platelet Services has signed a new lease to double its lab space at BioCity Nottingham, reflecting the year-on-year doubling of demand for the company’s core platelet function testing offering.

Platelet Services offers an array of standard and customised platelet testing assays to determine the effect of compounds on platelet function. Working with both small drug discovery companies and large pharmaceutical corporations, Platelet Services offers comprehensive support in drug discovery and development where platelet testing is required.

The additional space will allow the company’s project delivery and assay development services to proceed in parallel and will provide its team with more flexibility in delivering its core offering, with an anticipated shorter cycle time from agreeing a package of work with a client to the delivery of results.

Dr Natalia Dovlatova, CEO of Platelet Services, said: “With demand for our core platelet function testing offering rising significantly, this expansion of our lab space supports our continued growth strategy to broaden the range of test systems that Platelet Services is able to offer.

“Following the appointment of Paul Cato as senior research scientist earlier this year, we have ambitious plans to continue to expand our team with a focus on assay development. This is a really exciting time for Platelet Services, and we look forward to using the new space to strengthen our service offering and capabilities for the benefit of clients and further accelerate our growth.”